Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | CA9 | Q16790 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2295789 | 0.85 | CA12 (0.66) | LMNASMN1; SMN2CA12CA1CA2 | |
| SCHEMBL452918 | 0.84 | MEN1 (0.55) | LMNASMN1; SMN2CA12CA1CA2 | |
| SCHEMBL234454 | 0.83 | LMNA (0.62) | LMNASMN1; SMN2CA12CA1CA2 | |
| SCHEMBL8323868 | 0.83 | ALDH1A1 (0.60) | LMNASMN1; SMN2CA12CA1CA2 | |
| SCHEMBL3068668 | 0.82 | LMNA (0.57) | LMNASMN1; SMN2CA12CA1CA2 | |
| SCHEMBL1950181 | 0.82 | LMNA (0.61) | LMNASMN1; SMN2CA12CA1CA2 | |
| SCHEMBL11161020 | 0.82 | LMNA (0.61) | LMNASMN1; SMN2CA12CA1CA2 | |
| SCHEMBL9293730 | 0.81 | MGLL (0.55) | LMNASMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL25271685 | 0.81 | PLAU (0.45) | LMNASMN1; SMN2CA12CA1CA2 | |
| SCHEMBL2918702 | 0.81 | GAA (0.64) | LMNASMN1; SMN2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4664597-B2 | — | — | 2011-04-06 | — | — | JP | claimed |
| EP-1511734-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2010-06-23 | — | — | EP | claimed |
| US-20090005580-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2009-01-01 | — | — | US | claimed |
| US-20080312310-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. | 2008-12-18 | — | — | US | claimed |
| EP-1554265-A4 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2008-05-07 | — | — | EP | claimed |
| US-20070135432-A1 | Compounds, methods and compositions | CYTOKINETICS, INC. | 2007-06-14 | — | — | US | claimed |
| EP-1008590-B1 | Process for preparing optically active oxazolidinone derivatives | TAKASAGO PERFUMERY CO LTD (JP) | 2006-10-11 | — | — | EP | claimed |
| EP-1511734-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2006-05-10 | — | — | EP | claimed |
| EP-1503993-A4 | COMPOUNDS, METHODS AND COMPOSITIONS | CYTOKINETICS INC (US) | 2006-05-03 | — | — | EP | claimed |
| US-20060020008-A1 | Treating cell proliferation disorder, anticancer agents | CYTOKINETICS, INC. | 2006-01-26 | — | — | US | claimed |
| EP-1008590-A1 | Process for preparing optically active oxazolidinone derivative | Takasago International Corporation (JP) | 2000-06-14 | — | — | EP | claimed |
| EP-0973768-A1 | AZOLE COMPOUNDS, THEIR PRODUCTION AND THEIR USE | Takeda Chemical Industries, Ltd. (JP) | 2000-01-26 | — | — | EP | claimed |
| WO-1998043970-A1 | AZOLE COMPOUNDS, THEIR PRODUCTION AND THEIR USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-08 | — | — | WO | claimed |
| US-RE35886-E | ENDOTHELIN-CONVERTING ENZYME INHIBITOR | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-09-01 | — | — | US | claimed |
| EP-0825989-A1 | SUBSTITUTED OXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1998-03-04 | — | — | EP | claimed |
| WO-1996036617-A1 | SUBSTITUTED OXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-11-21 | — | — | WO | claimed |
| EP-0518299-A2 | Phosphonic acid derivatives, production and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-12-16 | — | — | EP | claimed |
| EP-0308885-A1 | Derivatives of d-glutamic acid and d-aspartic acid | ABBOTT LABORATORIES (US) | 1989-03-29 | — | — | EP | claimed |
| WO-1989002431-A1 | DERIVATIVES OF D-GLUTAMIC ACID AND D-ASPARTIC ACID | ABBOTT LABORATORIES (US) | 1989-03-23 | — | — | WO | claimed |
| US-4610983-A | N-acyl acidic amino acid diamide derivative, a salt thereof, and an anti-ulcer agent containing the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1986-09-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020008-A1 | Treating cell proliferation disorder, anticancer agents | MKI67, PCNA, TK1 | LMNA 2572/4885SMN1; SMN2 1962/4885CA12 3242/4885 |
| US-20080312310-A1 | Compounds, Compositions and Methods | ALPP, PCNA, MKI67 | LMNA 755/4885SMN1; SMN2 2785/4885CA12 1528/4885 |
| US-20090005580-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | LMNA 568/4885SMN1; SMN2 2102/4885CA12 1601/4885 |
| US-20070135432-A1 | Compounds, methods and compositions | ALPP, PCNA, MKI67 | LMNA 554/4885SMN1; SMN2 2350/4885CA12 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.